Marco-Rico Ana, Marco-Vera Pascual
Hemostasis and Thrombosis Department, Hematology Service, University General Hospital Dr. Balmis, Alicante, Spain.
Biomedical Research Institute (ISABIAL), Alicante, Spain.
J Blood Med. 2023 Sep 1;14:499-506. doi: 10.2147/JBM.S416355. eCollection 2023.
Congenital antithrombin (AT) deficiency represents the form of thrombophilia with the highest thrombotic risk. It is characterized by a heterogeneous clinical presentation, depending mostly on the family history of thrombosis and type of genetic mutation. Inherited AT deficiency promotes idiopathic thrombosis at an early age (even in the pediatric population) and at atypical sites. Therefore, a positive family background necessitates ruling out this high-risk thrombophilia at a young age. Studying first-degree relatives, even if they are asymptomatic, is essential to establish thromboprophylaxis and a proper therapeutic approach in case of thrombosis. Patients with congenital AT deficiency require indefinite anticoagulation owing to the high thrombotic recurrence rate. Here, we present four unrelated cases reported in our institution who were diagnosed with hereditary AT deficiency, with a contrasting clinical evolution.
先天性抗凝血酶(AT)缺乏症是血栓形成倾向中血栓形成风险最高的一种形式。其临床表现具有异质性,主要取决于血栓形成的家族史和基因突变类型。遗传性AT缺乏症会在早年(甚至在儿童群体中)和非典型部位引发特发性血栓形成。因此,阳性家族史需要在年轻时排除这种高风险的血栓形成倾向。对一级亲属进行研究,即使他们没有症状,对于确立血栓预防措施以及在发生血栓时采取适当的治疗方法至关重要。由于血栓复发率高,先天性AT缺乏症患者需要长期抗凝治疗。在此,我们介绍本院报告的4例无关病例,这些病例被诊断为遗传性AT缺乏症,其临床病程各不相同。